Co-Authors
This is a "connection" page, showing publications co-authored by Elizabeth Hill and Andrew Kraft.
Connection Strength
0.362
-
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.
Score: 0.191
-
A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood. 2010 Jan 28; 115(4):824-33.
Score: 0.089
-
Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin Cancer Res. 2019 02 01; 25(3):1036-1049.
Score: 0.041
-
PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. J Clin Invest. 2018 07 02; 128(7):2787-2801.
Score: 0.040